GIOVANNI RAIMONDO, M.D.; ANTONIO CRAXI, M.D.; GIUSEPPE LONGO, M.D.; GANDOLFO GIANNUOLI, M.D.; MARIA CALTAGIRONE, M.D.; MARCELLO ARAGONA, M.D.; GABRIELLA PECORARO, M.D.; GIUSEPPE SQUADRITO, M.D.; LUIGI PAGLIARO, M.D.
Chronic hepatitis B virus infection plays a major etio-logic role in hepatocellular carcinoma (1). In southern Italy, where the hepatitis B surface antigen (HBsAg) carrier status has an intermediate prevalence between high- and low-risk areas (2), hepatitis B virus has been confirmed as the main risk factor for hepatocellular carcinoma (3). In the same region superinfection of HBsAg carriers with the delta agent, a defective virus requiring helper functions of hepatitis B virus, is widespread and closely associated with chronic active liver disease (4). The prevalence of markers of delta infection in patients with HBsAg-positive hepatocellular carcinoma was compared to
RAIMONDO G, CRAXI A, LONGO G, GIANNUOLI G, CALTAGIRONE M, ARAGONA M, et al. Delta Infection in Hepatocellular Carcinoma Positive for Hepatitis B Surface Antigen. Ann Intern Med. ;101:343–344. doi: 10.7326/0003-4819-101-3-343
Download citation file:
Published: Ann Intern Med. 1984;101(3):343-344.
Gastroenterology/Hepatology, Gastrointestinal Cancer, Hematology/Oncology, Infectious Disease, Liver Cancer.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use